API Polpharma is a significant European producer of Active Pharmaceutical Ingredients delivering products to pharmaceutical companies worldwide. We are present on 6 continents, in 60+ countries, and our market share is constantly growing. Our well-balanced and expanding portfolio, along with our scientific know-how and experience, allow us to offer attractive solutions for drug developers.
We provide a one-stop shop solution of vertically integrated services from API development to FDF formulation and manufacturing, scale-up capabilities based on in-house or external custom developed technologies, to regulatory support. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (ASMF in eCTD format), PMDA (J-DMF) and FDA (US DMF). Our products are manufactured in accordance with the most stringent requirements of our customers and health authorities: USFDA, EMA, EDQM, SKFDA, PMDA, ANVISA, Polish Main Pharmaceutical Inspectorate. Regular FDA audits enabled us to register and sell a number of APIs in the US market and confirm our reliability and credibility towards our business partners around the world.
Comprised of highly skilled professionals, our Customer Service Team is committed to helping your business grow in the dynamic pharma environment. We put our customers at the core of what we do. Thus, in our ongoing effort to provide you the highest quality of service, we adopted the Kaizen methodology at the heart of which lies the idea of sustained continual improvement.
Our service establishes and enhances trust being the foundation of long-term business relations.
Polpharma is founded
– manufacturing on Bayer technology
Bayer takes over
Reconstruction of Polpharma after II World War. First product after the war - redistilled water in glass ampoules.
Minister of Industry establishes Starogard Pharmaceutical Plant
which starts producing salicylates
Starogard Pharmaceutical Plant becomes a part of the Union of Pharmaceutical Industry “Polfa” and is renamed to Starogard Pharmaceutical Works “Polfa”.
Polpharma transforms into a Joint Stock Company with 100% shares belonging to the State Treasury and returns to its old name - Pharmaceutical Works POLPHARMA S.A.
Spectra Holding and Prokom Investments (Polish capital) buy the majority of the Company shares converting it to a private company.
Strategic alliance with Akrikhin, major generic pharma player in the Russian market.
Acquisition of antibiotic business of Bioton Poland together with a cephalosporin manufacturing plant in Duchnice, Poland.
Polpharma becomes a major
shareholder of Akrikhin, Russia
Polpharma becomes a key partner of Chimpharm, Kazakhstan
Polpharma becomes a major shareholder of Polfa Warsaw, Poland